This activity is expired and is no longer available for CME credit.


Clinical Impact of Protocol T: 2-year Data

Author(s)/Faculty: Rishi P. Singh, MD; Felipe Ferreira Conti, MD; Grace J. Tsai, BA
Release Date: 3/29/2017Expiration Date: 3/28/2018
Credit Type: CMENumber of Credits: 0
Content Type: ArticleProvider:
Intravitreal pharmaceuticals have become the mainstay for retinal therapy. This activity will review the comparative efficacy and safety data from the Diabetic Retinopathy Clinical Research Network ( randomized clinical trial, Protocol T, which evaluated intravitreous aflibercept, bevacizumab, and ranibizumab for the treatment of diabetic macular edema.